Advanced search
Add to list

Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) assay utilizing low (0.1mg/70kg) and high (0.2mg/70kg) dose buprenorphine infusion and a novel USPIO contrast agent (Ferumoxytol) in healthy human subjects

Author
Organization
Abstract
We present results from a clinical trial of pharmaco-MRI (phMRI) employing cerebral blood volume (CBV) imaging using ferumoxytol (Rienso/Feraheme, AMAG) as a blood pool contrast agent. The study examined the pharmacodynamic effects of two single doses of buprenorphine (0.2mg/70kg and 0.1mg/70kg administered intravenously). We found that contrast-enhanced CBV phMRI signals are more sensitive reporters of pharmacodynamic effects than conventional blood oxygen level dependent (BOLD) phMRI. In particular, higher sensitivity of CBV phMRI compared to BOLD allows for elucidation of PD responses at lower doses of buprenorphine, which has practical implications for similar phMRI studies with centrally acting drugs.

Citation

Please use this url to cite or link to this publication:

MLA
Baumgartner, Richard, Arie Struyk, Jeff Evelhoch, et al. “Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) Assay Utilizing Low (0.1mg/70kg) and High (0.2mg/70kg) Dose Buprenorphine Infusion and a Novel USPIO Contrast Agent (Ferumoxytol) in Healthy Human Subjects.” Proceedings of the International Society of Magnetic Resonance in Medicine. Vol. 23. International Society of Magnetic Resonance in Medicine (ISMRM), 2015. Print.
APA
Baumgartner, R., Struyk, A., Evelhoch, J., Gargano, C., Gonzalez, F. C., Liu, H., Declercq, R., et al. (2015). Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) assay utilizing low (0.1mg/70kg) and high (0.2mg/70kg) dose buprenorphine infusion and a novel USPIO contrast agent (Ferumoxytol) in healthy human subjects. Proceedings of the International Society of Magnetic Resonance in Medicine (Vol. 23). Presented at the 23rd Annual meeting of the International Society of Magnetic Resonance in Medicine (ISMRM 2015), International Society of Magnetic Resonance in Medicine (ISMRM).
Chicago author-date
Baumgartner, Richard, Arie Struyk, Jeff Evelhoch, Cynthia Gargano, Francheska Colon Gonzalez, Haiying Liu, Ruben Declercq, et al. 2015. “Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) Assay Utilizing Low (0.1mg/70kg) and High (0.2mg/70kg) Dose Buprenorphine Infusion and a Novel USPIO Contrast Agent (Ferumoxytol) in Healthy Human Subjects.” In Proceedings of the International Society of Magnetic Resonance in Medicine. Vol. 23. International Society of Magnetic Resonance in Medicine (ISMRM).
Chicago author-date (all authors)
Baumgartner, Richard, Arie Struyk, Jeff Evelhoch, Cynthia Gargano, Francheska Colon Gonzalez, Haiying Liu, Ruben Declercq, Hans Verheyden, Ingeborg Heirman, HANS DE PLA, Griet Van Lancker, SOFIE VAN DEN ABEELE, ADELHEID HOLLEBOSCH, Brant Delafontaine, Lucas Van Bortel, Eric Achten, Patricia Clement, Pieter Vandemaele, Dai Feng, and Sofia Apreleva. 2015. “Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) Assay Utilizing Low (0.1mg/70kg) and High (0.2mg/70kg) Dose Buprenorphine Infusion and a Novel USPIO Contrast Agent (Ferumoxytol) in Healthy Human Subjects.” In Proceedings of the International Society of Magnetic Resonance in Medicine. Vol. 23. International Society of Magnetic Resonance in Medicine (ISMRM).
Vancouver
1.
Baumgartner R, Struyk A, Evelhoch J, Gargano C, Gonzalez FC, Liu H, et al. Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) assay utilizing low (0.1mg/70kg) and high (0.2mg/70kg) dose buprenorphine infusion and a novel USPIO contrast agent (Ferumoxytol) in healthy human subjects. Proceedings of the International Society of Magnetic Resonance in Medicine. International Society of Magnetic Resonance in Medicine (ISMRM); 2015.
IEEE
[1]
R. Baumgartner et al., “Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) assay utilizing low (0.1mg/70kg) and high (0.2mg/70kg) dose buprenorphine infusion and a novel USPIO contrast agent (Ferumoxytol) in healthy human subjects,” in Proceedings of the International Society of Magnetic Resonance in Medicine, Toronto, ON, Canada, 2015, vol. 23.
@inproceedings{8042029,
  abstract     = {We present results from a clinical trial of pharmaco-MRI (phMRI) employing cerebral blood volume (CBV) imaging using ferumoxytol (Rienso/Feraheme, AMAG) as a blood pool contrast agent. The study examined the pharmacodynamic effects of two single doses of buprenorphine (0.2mg/70kg and 0.1mg/70kg administered intravenously). We found that contrast-enhanced CBV phMRI signals are more sensitive reporters of pharmacodynamic effects than conventional blood oxygen level dependent (BOLD) phMRI. In particular, higher sensitivity of CBV phMRI compared to BOLD allows for elucidation of PD responses at lower doses of buprenorphine, which has practical implications for similar phMRI studies with centrally acting drugs.},
  author       = {Baumgartner, Richard and Struyk, Arie and Evelhoch, Jeff and Gargano, Cynthia and Gonzalez, Francheska Colon and Liu, Haiying and Declercq, Ruben and Verheyden, Hans and Heirman, Ingeborg and De Pla, Hans and Van Lancker, Griet and Van den Abeele, Sofie and Hollebosch, Adelheid and Delafontaine, Brant and Van Bortel, Lucas and Achten, Eric and Clement, Patricia and Vandemaele, Pieter and Feng, Dai and Apreleva, Sofia},
  booktitle    = {Proceedings of the International Society of Magnetic Resonance in Medicine},
  language     = {eng},
  location     = {Toronto, ON, Canada},
  publisher    = {International Society of Magnetic Resonance in Medicine (ISMRM)},
  title        = {Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) assay utilizing low (0.1mg/70kg) and high (0.2mg/70kg) dose buprenorphine infusion and a novel USPIO contrast agent (Ferumoxytol) in healthy human subjects},
  volume       = {23},
  year         = {2015},
}